Compare QFIN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QFIN | TNDM |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | China | United States |
| Employees | N/A | 2500 |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2018 | 2013 |
| Metric | QFIN | TNDM |
|---|---|---|
| Price | $7.33 | $15.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $22.20 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $8.11 |
| Revenue Next Year | N/A | $11.85 |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $7.44 | $11.46 |
| 52 Week High | $31.08 | $29.65 |
| Indicator | QFIN | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 19.35 | 34.22 |
| Support Level | N/A | $14.44 |
| Resistance Level | $14.03 | $16.50 |
| Average True Range (ATR) | 0.26 | 1.16 |
| MACD | 0.05 | -0.28 |
| Stochastic Oscillator | 0.57 | 16.67 |
Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.